St. Jude Medical and DuPont Merck Join Forces for Educational Programs on Anticoagulant Use with Mechanical Heart Valves

Strategic Insights -

St. Jude Medical, Inc., the manufacturer of the world's most preferred mechanical heart valves, has entered into an alliance with The DuPont Merck Pharmaceutical Company to jointly develop educational programs on the use of anticoagulants with mechanical heart valves. This partnership aims to enhance the cardiovascular disease management process by providing optimal anticoagulant management to St. Jude Medical mechanical heart valve patients. The educational alliance reflects the evolving healthcare market and the emerging need for comprehensive programs addressing specific disease needs.

Key Takeaways:

  • St. Jude Medical has entered into an alliance with DuPont Merck Pharmaceutical Company to develop educational programs on anticoagulant use with mechanical heart valves.
  • The partnership aims to enhance cardiovascular disease management by providing optimal anticoagulant management to St. Jude Medical mechanical heart valve patients.
  • DuPont Merck is the manufacturer of Coumadin(R), the leading anticoagulant medication used by patients with mechanical heart valves.
  • The educational alliance integrates the knowledge, expertise, and resources of both companies to support the healthcare of patients with mechanical heart valves who require anticoagulation.
  • St. Jude Medical has alliance partnerships with Advanced Tissue Sciences, Inc., Hancock Jaffe Laboratories, and The University of Michigan to provide solutions to heart valve disease.
  • DuPont Merck is a worldwide, research-based pharmaceutical company focused on research, development, and delivery of pharmaceuticals to treat unmet medical needs in the fight against heart disease, cancer, and AIDS.

Statistics:

  • Over 610,000 St. Jude Medical implants have been made.
  • DuPont Merck Pharmaceutical Company is a leader in radiopharmaceuticals.
  • The partnership aims to provide optimal anticoagulant management to patients with mechanical heart valves.
  • 18,260 heart valves planned for production.

Sources:

  • St. Jude Medical, Inc. press release, August 24, 1995.
  • The DuPont Merck Pharmaceutical Company profile.
  • St. Jude Medical Annual Report 1995.
  • DuPont Merck 1991 press release announcing the partnership between DuPont and Merck & Co., Inc.